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Abstract 
Background: The Plasmodium falciparum multidrug resistance 1 transporter, PfMDR1, contains five amino acid poly-
morphisms that are suggested to be involved in altered drug transport from the parasite’s cytosol into the digestive 
vacuole (DV). Transport of a substrate into another intracellular compartment influences drug availability at its site of 
action, therefore making the parasite more susceptible or resistant to a drug. Fluo-4 is a known fluorescent substrate 
that can be used as a molecular tool to investigate transport dynamics of PfMDR1 in many parasite strains.
Methods: Six P. falciparum strains with varying PfMDR1 mutations were loaded with Fluo-4 AM. Accumulation of the 
fluorophore in the DV was measured using confocal microscopy. The role of a key amino acid mutation was verified 
using selected parasite clones with point mutations at PfMDR1 amino acid position 1042. Equal expression of PfMDR1 
was confirmed by Western blot.
Results: Fluo-4 was transported by PfMDR1 into the DV of most drug-sensitive and -resistant parasites. Asparagine 
at PfMDR1 amino acid position 1042 was crucial for Fluo-4 transport, while the N1042D substitution abolished Fluo-4 
transport. Competition studies of Fluo-4 with chloroquine, quinine and mefloquine were performed on parasites har-
bouring asparagine at position 1042. A distinct Fluo-4 transport inhibition pattern for each tested anti-malarial drug 
was observed in parasite strains of different genetic background.
Conclusion: This study demonstrates that Fluo-4 can be used to investigate PfMDR1 transport dynamics in both 
drug-sensitive and -resistant parasites. Furthermore, direct evidence of altered Fluo-4 transport in PfMDR1 is linked to 
a single amino acid mutation in the substrate binding pocket. This system offers a great tool to investigate the role of 
substrate transport by PfMDR1 and the mutations necessary to support transport, which would lead to new insights 
for the development of novel anti-malarial drugs.
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Background
Emerging resistance to commonly used anti-malar-
ial drugs is a major setback in the fight against malaria 
worldwide [1]. Understanding the molecular mechanisms 
behind drug resistance is of high importance in ongoing 
efforts to control this disease.
Early on, researchers found a correlation between anti-
malarial resistance and the Plasmodium falciparum mul-
tidrug resistance 1 transporter (PfMDR1) [2, 3]. PfMDR1 
is a P-glycoprotein homologue (Pgh1) and belongs to the 
ATP binding cassette (ABC) transporter superfamily. It is 
a 162 kDa protein with two nucleotide binding domains 
(NBD) and twelve transmembrane domains (TMDs), 
with a putative substrate binding pocket in TMD11 [4]. 
The transporter is located in the membrane of the diges-
tive vacuole (DV) [5], transporting substrates from the 
parasite’s cytoplasm into the DV [6].
Two factors have been suggested to play a role in 
altered drug susceptibility to specific anti-malarial drugs: 
PfMDR1 polymorphisms and pfmdr1 gene duplications. 
Resistance has been associated with one or more varia-
tions at five amino acid positions in the PfMDR1 trans-
porter, with wild-type PfMDR1 containing the amino 
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acids N86, Y184, S1034, N1042, D1246. Increased pfmdr1 
copy numbers have been linked to mefloquine (MQ), 
lumefantrine (LF), halofantrine (HF), quinine (QN) and 
artemisinin (AS) resistance [7–9], while PfMDR1 amino 
acid mutations S1034C, N1042D, D1246Y were found to 
enhance parasite susceptibility to MQ, HF and AS, inde-
pendent of gene copy number [2, 10].
Additional evidence for altered drug transport in 
wild-type versus mutant PfMDR1 was shown through 
expression of different pfmdr1 variants in Xenopus laevis 
oocytes. Wild-type PfMDR1 transported QN and chlo-
roquine (CQ) but not HF, while mutant PfMDR1 trans-
ported HF but not QN or CQ [11]. Furthermore, residue 
184 altered transport kinetics independent of drug bind-
ing specificity [12].
Computational models of PfMDR1 describe a substrate-
binding pocket that includes the amino acid residues 1034 
and 1042 [4, 13]. The binding of several anti-malarial 
drugs was investigated using docking simulations within 
the PfMDR1 substrate-binding pocket. Among the tested 
drugs, MQ was the only candidate whose ability to form 
an H-bond with residue 1042 was completely abolished 
through the N1042D substitution [13].
Apart from anti-malarial drug transport, it was shown 
that several PfMDR1 drug-resistant variants could trans-
port the fluorescent substrate Fluo-4 into the DV of the 
parasite [6]. In contrast, Fluo-4 transport was abolished 
in drug-sensitive HB3 parasites harbouring the PfMDR1 
variant N86, F184, S1034, D1042, D1246. In a follow-up 
paper, the pump rate of PfMDR1 (F/Y86, Y184, S1034, 
N1042, D1246) was determined for Dd2 parasites using 
live cell imaging of intact infected erythrocytes [14].
In this study, drug-sensitive and -resistant P. falcipa-
rum strains of different genetic background and varying 
PfMDR1 polymorphisms were used to investigate the 
crucial mutations required for Fluo-4 transport. In addi-
tion, P. falciparum clones harbouring a  single mutation 
at position 1042 were analysed. Aspartic acid at position 
1042 was found to abolish Fluo-4 transport into the DV. 
This could be restored by replacing aspartic acid at posi-
tion 1042 with asparagine. Furthermore, the N1042D 
substitution resulted in increased sensitivity to MQ. 
Using Fluo-4 as a competitive substrate offers a power-
ful tool to investigate the role of PfMDR1 in transport of 
currently used anti-malarial drugs for both drug-sensi-
tive and -resistant parasites.
Methods
Parasite strains and culture conditions
Three CQ-sensitive (CQS) (3D7, D10, HB3) and three 
CQ-resistant (CQR) (Dd2, FCR3, FCB) P. falciparum 
strains, as well as stably transfected P. falciparum clones, 
derived from the parental lines GC03 and 3BA6, were 
used in this study. The two strains GC03 and 3BA6 are 
progeny of the HB3 ×  Dd2 genetic cross [15] and har-
bour the PfMDR1 variant from HB3 but differ in their 
PfCRT phenotype and genotype (Table  1). PfMDR1 
mutants derived from GC03 and 3BA6 were produced 
by Sidhu and colleagues through partial pfmdr1 gene 
replacement that substituted aspartic acid at position 
1042 with asparagine while leaving amino acids at resi-
dues 1034 and 1246 unchanged. The resulting clones 
were: SNDGC03 (S1034, N1042, D1246 in a GC03 genetic 
background), SND3BA6 (S1034, N1042, D1246 in a 3BA6 
Table 1 Main PfCRT and PfMDR1 mutations of Plasmodium falciparum parasites used in this study
PfCRT PfMDR1
76 86 184 1034 1042 1246
Strains
HB3 K N F S D D
3D7 K N Y S N D
D10 K N Y S N D
Dd2 T Y/F Y S N D
FCR3 T Y Y S N D
FCB T Y Y S N D
Clones
GC03 K N F S D D
SDDGC03 K N F S D D
SNDGC03 K N F S N D
3BA6 T N F S D D
SDD3BA6 T N F S D D
SND3BA6 T N F S N D
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genetic background), as well as the recombinant con-
trols SDDGC03 and SDD3BA6 [10]. All strains were cul-
tured continuously, as described by Trager and Jensen 
[16], with modifications. Briefly, parasites were propa-
gated at 5% haematocrit in culture medium containing 
RPMI 1640 (Life Technologies, Burlington, ON, Canada) 
supplemented with 25  mM HEPES, 2  mM l-glutamine, 
gentamicin (20  µg/ml) (Life Technologies, Burlington, 
ON, Canada), 100  µM hypoxanthine (Sigma-Aldrich, 
Oakville, ON, Canada), 0.5% AlbuMAX I (Life Technolo-
gies, Burlington, ON, Canada). Parasites were maintained 
at 37°C with an atmosphere of 5% CO2, 3% O2 and 92% 
N2. A+ red blood cells were obtained from the Interstate 
Blood Bank (Memphis, TN, USA). Giemsa-stained blood 
smears were prepared daily to monitor parasite growth. 
For synchronization, parasites were treated with 5% 
d-sorbitol (BioShop Canada, Burlington, ON, Canada) 
for 10  min at 37°C; sorbitol was removed and parasites 
were washed once before putting them back into culture. 
To obtain highly synchronous parasite cultures, sorbitol 
treatment was repeated after 6–8 h.
DNA isolation and sequence analysis
The full-length sequence of pfmdr1 and partial sequence 
of pfcrt was verified for all strains. Parasite strains were 
grown to ≥5% parasitaemia and DNA was extracted using 
the QIAamp DNA Blood Mini Kit (Qiagen, Toronto, 
ON, Canada) according to manufacturer’s instructions. 
DNA was amplified in overlapping PCR fractions using 
HotStarTaq DNA polymerase (Qiagen, Toronto, ON, 
Canada). To account for the AT-rich nucleotide content 
in the P. falciparum genome, dNTPs (Invitrogen Canada, 
Burlington, ON, Canada) were mixed at 75% AT and 
25% GC. For PCR optimization, 2  mM MgCl2, 300  µM 
dNTPs and 300  nM primers were used for the reaction. 
For each reaction mix, 20  ng genomic DNA was used. 
PCR reactions consisted of an initial activation step of 
94°C for 3  min, followed by 35 cycles of 94°C for 60  s, 
49–61°C (adjusted for each primer pair) for 30  s, and 
72°C for 1  min. Primers used for pfmdr1 gene sequenc-
ing are described in [14]. Primers used for sequencing 
the pfcrt gene region containing the main mutation sites 
were: pfcrt_F: 5′-GGAGGTTCTTGTCTTGGTAAATG, 
pfcrt_R: 5′-TGGTAGGTGGAATAGATTCTCTTATAAA. 
Samples were sent for sequencing to Genome Quebec, 
Canada and analysed using the BioEdit software [17].
Protein expression
To determine PfMDR1 protein levels, 20  µg whole cell 
protein lysates were loaded in each lane of an 8% acryla-
mide gel containing SDS. The proteins were transferred 
onto a PVDF membrane, which was then blocked O/N 
at 4°C with 5% milk (w/v) and 0.05% Tween-20 (ACP 
Chemicals, St-Leonard, QC, Canada) in phosphate buff-
ered saline (PBS). The membrane was further incubated 
with the appropriate dilution of primary anti-PfMDR1 
(kindly provided by Prof Cowman, Walter and Eliza 
Hall Institute, VIC, Australia) or anti-PfHSP70 (Gen-
Way Biotech, San Diego, CA, USA) antibody (1:2,000) in 
PBS-T +  5% milk for 1  h (RT), then washed and incu-
bated with HRP-conjugated anti-rabbit IgG secondary 
antibody (Abcam, Toronto, ON, Canada) (1:20,000) for 
1  h (RT). Immunoreactive bands were detected with 
ImmunStar WesternC Chemiluminescent Kit (Bio-Rad 
Laboratories, Mississauga, ON, Canada) using a myECL 
Imager (Thermo Scientific, Burlington, ON, Canada). To 
confirm equal protein loading, chemiluminescence inten-
sities of PfMDR1 were calculated for each parasite clone 
relative to the respective PfHSP70 chemiluminescence 
using ImageJ 1.47q (National Institutes of Health, USA).
Growth inhibition assay
Growth inhibition assays were performed as described 
previously [18], with modifications. Briefly, synchronized 
ring stage parasites were diluted to a final parasitaemia 
of 0.5% and a haematocrit of 2%. A total of 100 µl culture 
medium per well was prepared in a 96-well plate assay, 
with a drug dilution series of 1:3, ranging from 1 µM to 
0.15 nM. Plates were incubated at 37°C, 5% CO2, 3% O2 
and 92% N2 for 72  h, then frozen and stored at −80°C. 
Plates were thawed at room temperature and 100 µl 2× 
lysis buffer (20  mM Tris pH 7.5, 5  mM EDTA, 0.008% 
saponin, 0.08% Triton X-100, 0.2  µl SYBR Green I/ml) 
was added to each well. Plates were incubated in the 
dark for at least 1  h. Fluorescence intensity was deter-
mined using a Synergy H4 plate reader (Fisher Scien-
tific, Nepean, ON, Canada) with 485  nm excitation and 
520  nm emission wavelengths. IC50 values were deter-
mined by fitting concentration response curves with a 
custom-made procedure for IGOR Pro 6.2 based on an R 
script kindly provided by Le Nagard [19, 20].
Live cell imaging
Synchronized trophozoite stage parasites were loaded 
with 5  µM Fluo-4 AM (Life Technologies, Burlington, 
ON, Canada) in Ringer’s solution (122.5  mM NaCl, 
5.4  mM KCl, 1.2  mM CaCl2, 0.8  mM MgCl2, 11  mM 
d-glucose, 10 mM HEPES, 1 mM NaH2PO4, pH 7.4) for 
50 min at 37°C. Cells were then washed twice with Ring-
er’s solution and transferred to a microscope chamber. 
Parasites were kept at 37°C during microscopy using a 
stage-top incubator (Tokai Hit, Shizuoka-ken, Japan). A 
series of four images per parasite was taken using a Zeiss 
LSM710 confocal microscope (Carl Zeiss, Oberkochen, 
Germany) equipped with a water-corrected objective 
(C-apochromat 63×/1.20  W Korr M27) and a 488  nm 
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laser (12.5 mW, 2% intensity). The range of emitted flu-
orescence was measured from 493 to 622  nm. Images 
were analysed using ImageJ 1.47q (National Institutes of 
Health, USA).
Results and discussion
PfMDR1 transports Fluo‑4 into the digestive vacuole
A genetic linkage between Fluo-4 accumulation in 
the DV and the PfMDR1 transporter was previously 
described [6]. Although variations in Fluo-4 accumula-
tion were observed between parasite strains harbouring 
different PfMDR1 mutations, the amino acid mutation(s) 
responsible for Fluo-4 transport remained to be deter-
mined. To identify PfMDR1 mutation(s) crucial for 
Fluo-4 transport, several drug-sensitive and -resistant P. 
falciparum strains of different genetic backgrounds were 
tested for accumulation of Fluo-4 in the DV. Three CQS 
and three CQR strains harbouring different PfMDR1 
mutations were selected for these experiments (Table 1). 
While PfMDR1 has been suggested to play a role in CQ 
resistance, the key genetic indicator for CQS versus CQR 
parasites is attributed to the amino acid mutation K76T 
in the P. falciparum chloroquine resistance transporter 
(PfCRT) [21]. This mutation was taken into considera-
tion in this study and the relevance of PfMDR1 polymor-
phisms is discussed for strains harbouring either lysine 
(K76) or threonine (K76T) in PfCRT.
Of the five mutation sites in PfMDR1 known to play a 
role in drug resistance, the parasite strains used for these 
experiments contained mutations at amino acid positions 
86, 184 and 1042, which are mainly found in African and 
Asian isolates [7, 22–24]. To determine if mutations at 
these residues influence transport of Fluo-4 via PfMDR1, 
accumulation of Fluo-4 in the DV was measured in live 
parasites using confocal microscopy. All parasite strains, 
except HB3, showed high accumulation of Fluo-4 in 
the DV (Figure  1a, b). Fluo-4 accumulation in the DV 
was impeded by pre-incubation of the parasites with 
tariquidar (TQ) (Figure  1b), a specific inhibitor of Pgp 
transporters [25]. Importantly, Fluo-4 accumulation in 
the DV was shown to be independent of the PfCRT K76T 
mutation, suggesting that the PfCRT mutation alone has 
no effect Fluo-4 accumulation.
Fluo‑4 transport is associated with PfMDR1 N1042
The parasite strain HB3, which does not accumulate 
Fluo-4 in the DV, harbours two PfMDR1 polymor-
phisms—Y184F and N1042D—not found in the other 
tested P. falciparum strains (Table 1), suggesting that one 
of these two residues is responsible for the altered Fluo-4 
transport seen in HB3 parasites. It has previously been 
demonstrated for the human homolog of PfMDR1 that 
the Y184F mutation does not influence drug specific-
ity [12]. Furthermore, this residue only mildly increased 
drug resistance in comparison to other PfMDR1 muta-
tion sites [4]. In contrast, amino acid position 1042 is 
thought to be part of the transporter binding pocket and 
forms electrostatic interactions with amodiaquine, CQ, 
MQ (only in the presence of asparagine), HF, vinblastine 
and vincristine [4, 10, 13]. Therefore, the role of PfMDR1 
mutations at position 1042 was investigated in more 
detail.
To verify the influence of PfCRT on Fluo-4 transport, 
existing parasite clones containing either lysine or threo-
nine at residue 76 in PfCRT were selected and compared. 
For this, stably transfected P. falciparum clones derived 
from the parental lines GC03 and 3BA6 were used, where 
GC03 harbours the K76 PfCRT genotype and is CQ sen-
sitive, and 3BA6 contains the PfCRT K76T mutation that 
confers CQ resistance (Table  1). Both GC03 and 3BA6 
contain the PfMDR1 sequence N86, F184, S1034, D1042, 
D1246, identical to the HB3 strain. Experiments verified 
that neither GC03 nor 3BA6 were able to accumulate 
Fluo-4 in the DV, as expected (Figure 2a, b).
As a control, parasite clones SDDGC03 and SDD3BA6, 
harbouring the same mutation as GC03 and 3BA6, 
revealed that the PfMDR1 N1042D mutation did not 
transport Fluo-4 into the DV (Figure  2a, b). Fluo-4 
transport was only established with the introduction 
of asparagine at residue 1042 for both clones (SNDGC03 
and SND3BA6). Transport was independent of the PfCRT 
K76T mutation, since Fluo-4 transport was equally 
impaired in GC03 and 3BA6 parental lines as well as 
the SDDGC03 and SDD3BA6 controls, and only seen in the 
clones SNDGC03 and SND3BA6 (Figure  2a, b). Transport 
specificity for PfMDR1 in clones SNDGC03 and SND3BA6 
was confirmed through pre-incubation of the samples 
with the Pgp inhibitor TQ (Figure  2b; Additional file  1: 
Figure S1). These results indicate a pivotal role for aspar-
agine at PfMDR1 residue 1042 in Fluo-4 transport, inde-
pendent of PfCRT.
In addition to PfMDR1 polymorphisms, increased 
pfmdr1 gene copy number [8, 9, 26] and protein expres-
sion levels have also been suggested to play a role in drug 
resistance or susceptibility. To verify that Fluo-4 accumu-
lation in the DV of clones SNDGC03 and SND3BA6 was not 
linked to increased PfMDR1 expression, PfMDR1 protein 
levels were analysed for these parasite clones (Figure 2c). 
No significant increase in PfMDR1 expression was 
detected for the GC03 and 3BA6 parental lines or their 
clones harbouring the D1042N substitution (p  >  0.05). 
Therefore, Fluo-4 accumulation in the DV of these clones 
was only associated with the PfMDR1 mutation at resi-
due 1042.
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Effect of N1042D polymorphism on drug susceptibility
Since transport of Fluo-4 was dependent on specific 
PfMDR1 polymorphisms, it follows that the N1042D 
substitution in the PfMDR1 substrate-binding pocket 
may not only alter the binding and transport of Fluo-4 
but also influence other substrates, such as anti-malarial 
drugs. To determine if the amino acid substitution at 
residue 1042 resulted in altered drug sensitivity or resist-
ance of the parasite clones, growth inhibition assays were 
performed. A change in a given drug’s IC50 would indi-
cate a role for PfMDR1 amino acid position 1042 in its 
transport. CQ IC50 values for CQS clones were found to 
Figure 1 Fluo-4 fluorescence in P. falciparum parasites. Parasites were incubated with 5 µM Fluo-4. a Representative images of P. falciparum-
infected erythrocytes. Scale bar 5 µm. b Mean Fluo-4 fluorescence ratio (DV/cytosol) ± SEM. When treated with the Pgp inhibitor tariquidar (TQ), 
fluorescence ratio was reduced, indicating that Fluo-4 transport occurred exclusively through PfMDR1. Total n ≥ 67 for each strain, done in three 
independent experiments on different days.
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be 47 ± 2.6 nM for GC03, 46 ± 2.2 nM for SDDGC03 and 
49 ± 2.8 nM for SNDGC03, while CQ IC50 values for CQR 
clones were 262 ±  5.7  nM for 3BA6, 204 ±  9.4  nM for 
SDD3BA6 and 274 ± 5.6 nM for SND3BA6 (Table 2). This 
suggests that an amino acid mutation at PfMDR1 resi-
due 1042 does not affect susceptibility or resistance to 
CQ. CQ resistance could be reversed in the CQR strains 
through the addition of 1 µM verapamil, while no signifi-
cant difference was observed in CQS strains (p > 0.05), as 
expected. Similarly, CQS clones were more susceptible 
to quinacrine (QC) with IC50 values of 11  ±  0.3  nM 
for GC03, 13 ±  0.3  nM for SDDGC03 and 14 ±  0.4  nM 
for SNDGC03 compared to the higher QC IC50 values of 
43  ±  3.4  nM for 3BA6, 41  ±  1.0  nM for SDD3BA6 and 
42  ±  2.3  nM for SND3BA6. Here again, as for CQ, an 
amino acid mutation at PfMDR1 residue 1042 did not 
affect susceptibility or resistance to QC. The same was 
found for dihydroartemisinin (DHA). CQS clones were 
fourfold more resistant than CQR clones (4  ±  0.1 vs 
1 ±  0.1  nM) and DHA resistance was not reversible by 
Figure 2 Fluo-4 fluorescence in P. falciparum clones with varying PfMDR1 and PfCRT mutations. Parasites were incubated with 5 µM Fluo-4 AM 
in Ringer’s solution for 50 min at 37°C, then washed with Ringer’s solution and transferred onto a microscope chamber. a Single images of P. 
falciparum clones. Scale bar 5 µm. b Mean Fluo-4 fluorescence ratio measured from the digestive vacuole (DV) and the cytosol. When treated with 
tariquidar (TQ), parasites were pre-incubated with 100 nM TQ for 10 min at 37°C before adding Fluo-4 AM for 50 min. Total n ≥ 80 for each strain, 
done in three independent experiments on different days. Error bars represent SEM. ***p < 0.0001. c Western blot of synchronized trophozoite stage 
parasites using anti-PfMDR1 antibodies. Anti-PfHSP70 was used as a loading control. PfMDR1 protein expression levels were normalized to PfHSP70 
and measured in triplicate ± SEM.
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the addition of 1 µM verapamil. Therefore, the PfMDR1 
N1042D mutation alone does not appear to be a major 
determinant for CQ, QC or DHA resistance in these par-
asites (Table 2).
Interestingly, the N1042D mutation did provide 
changes in drug susceptibility for the anti-malarial drugs 
QN and MQ. A significant decrease in QN IC50 values 
was observed in the GC03 and 3BA6-derived clones 
SNDGC03 and SND3BA6 compared to the parental lines 
GC03 and 3BA6 or their recombinant controls SDDGC03 
and SDD3BA6 (p  <  0.005) (Table  2), which is in agree-
ment with previous findings [10]. The opposite effect was 
observed for MQ. For the clones SNDGC03 and SND3BA-
6clones, the D1042N substitution led to an approximate 
threefold increase in resistance to MQ. MQ IC50 values 
increased from 6 ± 0.9 nM in GC03 to 19 ± 0.6 nM in 
SNDGC03, and from 5 ± 0.3 nM in 3BA6 to 14 ± 0.5 nM 
in SND3BA6. This was a significant increase in MQ IC50 
values for the clones SNDGC03 and SND3BA6 compared 
to the parental lines (p =  0.0003 for GC03 vs SNDGC03; 
p  =  0.0001 for 3BA6 vs SND3BA6). Similar increases in 
MQ resistance (approximately threefold) have been 
found in field isolates from Africa and Asia [27, 28]. A 
threefold increase in MQ resistance was also confirmed 
in vitro through allelic exchange of pfmdr1 [2]. Therefore, 
the PfMDR1 mutation crucial for MQ resistance in vitro 
is likely to play a role in increased MQ resistance in the 
field. Nevertheless, growth inhibition experiments do 
not fully elucidate altered transport of MQ by PfMDR1. 
For this reason, co-incubation of anti-malarial drugs 
with Fluo-4 can provide additional insight into the role 
of PfMDR1 transport in drug resistance.
Substrate competition of anti‑malarial drugs with Fluo‑4 
to determine drug transport by PfMDR1
PfMDR1 is involved in the transport of substrates, includ-
ing various anti-malarial drugs, from the cytosol into the 
DV [10, 11] but the role of PfMDR1 polymorphisms in 
drug resistance is not fully understood. Mutations at resi-
due 86 has been suggested to allosterically influence the 
TMD11 drug binding site [4], while PfMDR1 residues 
1034 and 1042 are located in a proposed binding pocket. 
Electrostatic interactions with both asparagine and 
aspartic acid at position 1042 have been demonstrated in 
silico for CQ, QN and MQ [4, 13]. While CQ was unable 
to form a hydrogen (H)-bond with either asparagine or 
aspartic acid at residue 1042, asparagine at residue 1042 
was able to form a H-bond with MQ [4, 13]. No informa-
tion is available on H-bond formation of QN with residue 
1042.
Further insight into the importance of PfMDR1 in drug 
transport can be achieved through competition studies 
using two potentially competitive substrates, e.g., fixed 
amounts of Fluo-4 and increasing drug concentrations. 
For this purpose, two parasite strains were chosen to 
evaluate potential differences in anti-malarial drug trans-
port in sensitive (3D7) and resistant (Dd2) parasites. 3D7 
is sensitive to CQ, QN and MQ (Table  2), while Dd2 is 
resistant to these drugs. HB3 was not used, since it is 
not able to transport Fluo-4 into the DV. The measured 
changes of Fluo-4 accumulation in the DV in the pres-
ence of anti-malarial drugs were compared for 3D7 and 
Dd2 parasites.
For 3D7 parasites, increasing CQ concentration led to 
the strong decrease in Fluo-4 accumulation in the DV 
(Figure  3a). While TQ is a non-competitive inhibitor of 
MDR1 through inhibition of the ATPase activity [25], CQ 
is thought to bind to the transporter’s substrate-binding 
pocket and is likely a competitive inhibitor of Fluo-4. Pre-
incubation of 3D7 parasites with 250  nM CQ resulted 
in decreased Fluo-4 accumulation in the DV, where 
only 5  ±  1.0% Fluo-4 fluorescence was measured when 
compared to non drug-treated parasites. In Dd2 para-
sites, pre-incubation with 250  nM CQ reduced Fluo-4 
Table 2 IC50 values of Plasmodium falciparum parasites used in this study
All values are given in nM. Experiments were done in triplicate on three separate days.
CQ chloroquine, VP verapamil, DHA dihydroartemisinin, QC quinacrine, QN quinine, MQ mefloquine, n.d. not determined.
CQ CQ + VP DHA DHA + VP QC QC + VP QN MQ
3D7 24 ± 5.6 17 ± 1.2 n.d. n.d. n.d. n.d. 23 ± 1.8 8 ± 1.2
Dd2 169 ± 3.9 53 ± 6.5 n.d. n.d. n.d. n.d. 283 ± 39.8 27 ± 4.0
GC03 47 ± 2.6 46 ± 2.1 4 ± 0.1 4 ± 0.1 11 ± 0.3 18 ± 0.4 85 ± 9.6 6 ± 0.9
SDDGC03 46 ± 2.2 47 ± 0.6 4 ± 0.1 3 ± 0.2 13 ± 0.3 15 ± 0.7 76 ± 4.9 7 ± 0.6
SNDGC03 49 ± 2.8 47 ± 2.2 4 ± 0.1 3 ± 0.1 14 ± 0.4 17 ± 0.3 52 ± 3.5 19 ± 0.6
3BA6 262 ± 5.7 41 ± 1.8 1 ± 0.1 1 ± 0.1 43 ± 3.4 47 ± 2.2 83 ± 4.8 5 ± 0.3
SDD3BA6 204 ± 9.4 63 ± 1.5 1 ± 0.0 1 ± 0.1 41 ± 1.0 39 ± 0.5 78 ± 5.3 6 ± 0.7
SND3BA6 274 ± 5.6 69 ± 5.6 1 ± 0.1 1 ± 0.0 42 ± 2.3 39 ± 0.4 48 ± 2.4 14 ± 0.5
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Figure 3 Competition of Fluo-4 transport with anti-malarial drugs. a Parasites were pre-incubated with different concentrations of chloroquine 
(CQ), mefloquine (MQ) or quinine (QN), or left untreated before adding Fluo-4 AM. b Parasites were pre-incubated as described with 250 nM of CQ, 
MQ or QN. Experiments were done in triplicate 3 independent days. Error bars represent SEM. *P < 0.05; ***P < 0.0001.
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fluorescence in the DV by half (48 ± 3.0%). MQ reduced 
Fluo-4 transport into the DV to 45 ± 2.0% in 3D7 para-
sites and only 82 ± 6.0% in Dd2 parasites (Figure 3a). For 
MQ, a decrease in Fluo-4 transport in 3D7 compared to 
Dd2 parasites  cannot be attributed to a PfMDR1 amino 
acid mutation at position 1042 alone since both strains 
harbour wild-type N1042. However, Dd2 parasites har-
bour an amino acid mutation at PfMDR1 residue 86, 
which was described to influence MQ sensitivity in Afri-
can field isolates [24, 30, 31]. This N86Y mutation may 
alter MQ transport by PfMDR1, as shown in the experi-
ments presented here. QN was less effective in reducing 
Fluo-4 accumulation than CQ or MQ and only decreased 
Fluo-4 fluorescence in the DV to 59 ± 2.9% in 3D7 para-
sites and not significantly in Dd2 parasites (92  ±  3.4%) 
(Figure 3a). The differences between 3D7 and Dd2 para-
sites at the level of Fluo-4 reduction may be linked to 
PfMDR1 residue 86, which is suggested to influence CQ 
susceptibility [29]. It is conceivable that N86Y can allos-
terically influence the drug binding site at TMD11, as sug-
gested in [4]. Residue 86 was not examined in this study.
Fluo-4 competition with anti-malarial drugs was also 
tested on the parasite clones SNDGC03 and SND3BA6. 
Using a single drug concentration of 250  nM, Fluo-4 
accumulation was decreased in the DV of SNDGC03 and 
SND3BA6 parasites to 33 ±  1.9% and 39 ±  3.0% for CQ, 
61 ±  3.1% and 65 ±  4.8% for MQ, and 58 ±  3.9% and 
91  ±  4.4% for QN, respectively. Almost all tested anti-
malarial drugs decreased Fluo-4 accumulation in the 
DV in both SNDGC03 and SND3BA6 clones, except for QN 
(Figure 3b). This again suggests that the influence of anti-
malarial drugs on substrate transport by PfMDR1 is not 
only dependent on PfMDR1 polymorphisms but also on 
the varying genetic background of the parasite strain.
The influence of the N1042D substitution on Fluo-4 
transport is explained in a proposed model (Figure  4). 
Fluo-4 is negatively charged and replacement of a neu-
tral asparagine at residue 1042 with a negatively charged 
aspartic acid alters the local environment, making it 
less favourable to Fluo-4  transport. TQ does not influ-
ence Fluo-4 affinity for the substrate-binding pocket 
but prevents adenosine triphosphate (ATP) hydrolysis 
of PfMDR1. Since both NBDs act in concert [32], com-
plete inhibition of ATPase activity by TQ can be achieved 
when one nucleotide-binding site is blocked.
Detailed transport kinetics for parasite strains of dif-
ferent origin will provide additional information on 
substrate transport via PfMDR1. Using Fluo-4 as a com-
petitive substrate circumvents the issue of direct label-
ling of anti-malarial drugs with a fluorescent tag that 
may alter their transport properties. Therefore, Fluo-4 is 
a powerful tool to selectively study transport kinetics of 
PfMDR1 in intact P. falciparum-infected erythrocytes.
Conclusion
This study provides direct evidence for reduced 
PfMDR1-driven substrate transport through the sin-
gle amino acid mutation N1042D, located in the sub-
strate-binding pocket. The relevance of this amino acid 
Figure 4 Model of Fluo-4 transport. The docking of substrates in 
the PfMDR1 binding pocket is influenced by the size, charge and 
polarity of local amino acids. Asparagine (N) and aspartic acid (D) are 
both polar, hydrophilic and small in volume. While N is an amide and 
uncharged, D is acidic and negatively charged. a For parasites con-
taining the PfMDR1 N1042 polymorphism, the intrinsically negatively 
charged Fluo-4 gets transported from the cytoplasm into the diges-
tive vacuole (DV) where it accumulates. b In the presence of PfMDR1 
N1042D, which adds a negative charge to the binding pocket, Fluo-4 
does not get transported by PfMDR1 and no Fluo-4 accumulation 
is detected in the DV. c Fluo-4 transport is abolished through the 
addition of the Pgp inhibitor tariquidar (TQ), which does not alter 
the substrate binding but prevents ATP hydrolysis and therefore the 
conformational change that is necessary for substrate dislocation.
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mutation may have been underestimated and needs 
further investigation. Furthermore, it is now possible to 
test additional mutations within the binding pocket of 
PfMDR1 to verify their potential role in drug transport. 
Accordingly, using Fluo-4 in drug competition assays 
provides a powerful tool to better examine drug trans-
port kinetics via PfMDR1. This newly acquired infor-
mation can help elucidate the role of PfMDR1 in drug 
transport, which has remained controversial for dec-
ades. For example, while earlier investigations have sug-
gested a link between MQ resistance and asparagine at 
PfMDR1 amino acid position 86 in isolates from Thai-
land and West Africa [30, 33], others have associated 
wild-type PfMDR1 and increased gene copy numbers 
with MQ resistance [3, 34]. More recent publications 
have found strong evidence for a role for N1042 in MQ 
resistance in Thai isolates [35, 36], suggesting that the 
importance of this mutation has been underestimated 
in previous field studies. The importance of N1042 for 
MQ resistance was similarly demonstrated in  vitro 
through combined amino acid substitutions that gener-
ated a parasite strain harbouring the mutations S1024C, 
N1042D, D1246Y [2]. This newly generated strain was 
approximately threefold more susceptible to MQ expo-
sure compared to the parental strain [2]. The results 
presented here support a potential role of PfMDR1 
N1042 in parasite resistance to MQ. Further investiga-
tions will help elucidate the significance of this poly-
morphism on substrate transport.
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